publication date: May. 8, 2015

Theodorescu and Lerner Named Editors-in-Chief of Bladder Cancer


DAN THEODORESCU and SETH LERNER were named editors-in-chief of the new journal Bladder Cancer.

Theodorescu is director of the University of Colorado Cancer Center and is a professor of urology and pharmacology at the University of Colorado School of Medicine.

Lerner is the Beth and Dave Swalm Chair in Urologic Oncology and is director of the Multidisciplinary Bladder Cancer Program at Baylor College of Medicine.

The multi-disciplinary journal will specialize in all things related to the disease, including understanding of the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract.

“I’ve been studying bladder cancer for 20 years and it’s gratifying to be part of this journal from its inception,” says Theodorescu. “We want Bladder Cancer to provide a clearing house for information about breakthroughs in basic science, translational research and patient care.”

Theodorescu manages an active translational molecular biology lab focused on the mechanisms leading to bladder cancer growth and metastasis. He also has been involved in the discovery, development and testing of COXEN (CO-eXpression ExtrapolatioN), a precision medicine strategy to predict which tumors will be sensitive to which drugs based on genetic analysis of tumor samples.

He also led the team that in 2014 described the first drug against Ral, an oncogene that contributes to several cancer types including bladder, pancreas, lung, colon and prostate.

Lerner is author of … Continue reading 41-18 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.